

CORRECTION

Open Access



# Correction: Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy

Yu-An Li<sup>1†</sup>, Chuan Zhao<sup>1†</sup>, Jing-Jing Ge<sup>1</sup>, Cheng Li<sup>1</sup>, Feng-Jun Xue<sup>1</sup>, Shao-Pei Qi<sup>1</sup>, Chi Zhao<sup>1</sup>, Chen-Chen Kong<sup>1</sup> and Jun-Ping Zhang<sup>1\*</sup>

**Correction:** *BMC Cancer* 24, 754 (2024)  
<https://doi.org/10.1186/s12885-024-12373-9>

Following publication of the original article [1], a typesetting error was reported. The equal contribution statement was missing in the published article. YuAn Li and Chuan Zhao are co-first authors.

The original article [1] has been corrected.

Published online: 11 July 2024

## References

1. Li YA, Zhao C, Ge JJ, et al. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy. *BMC Cancer*. 2024;24:754. <https://doi.org/10.1186/s12885-024-12373-9>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

<sup>†</sup>Yu An Li and Chuan Zhao are co-first authors.

The online version of the original article can be found at <https://doi.org/10.1186/s12885-024-12373-9>.

\*Correspondence:

Jun-Ping Zhang  
doczhjp@mail.ccmu.edu.cn

<sup>1</sup>Department of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University, Beijing, China

